Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly

CONCLUSIONS: The safety and tolerability profile was in-line with the known safety profile of lanreotide autogel. Lanreotide PRF was well tolerated and the pharmacokinetic profile suggests that a dosing interval of 12 weeks could be achievable.CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT02396953; EudraCT 2014-002389-62.PMID:34664531 | DOI:10.1080/17512433.2021.1986004

https://pubmed.ncbi.nlm.nih.gov/34664531/?utm_source=no_user_agent&utm_medium=rs...

Source: Expert Review of Clinical Pharmacology - October 19, 2021 Category: Drugs & Pharmacology Authors: Sebastian Neggers Corin Badiu Betina Biagetti Lucie Durand-Gasselin Anne Petit Patrick Petrossians Benjamin Regnault David Rich Zulfiya Shafigullina Sergey Shustov Anna Vydrych Source Type: research